{
    "clinical_study": {
        "@rank": "109205", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (sargramostim and sentinel lymph node biopsy)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy."
            }, 
            {
                "arm_group_label": "Arm II (hypertonic saline and sentinel lymph node biopsy)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to\n      see how well it works compared to hypertonic saline before sentinel lymph node biopsy in\n      treating patients with melanoma. Biological therapies, such as sargramostim, may stimulate\n      the immune system in different ways and stop cancer cells from growing. It is not yet known\n      whether sargramostim is more effective than hypertonic saline in treating patients with\n      stage IB-II melanoma undergoing sentinel lymph node biopsy."
        }, 
        "brief_title": "Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma", 
        "condition": [
            "Stage IB Melanoma", 
            "Stage IIA Melanoma", 
            "Stage IIB Melanoma", 
            "Stage IIC Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine if the alterations in morphology and phenotype to the sentinel lymph nodes\n      are reversible.\n\n      II. To determine if the restoration of the morphology or phenotype of sentinel lymph nodes\n      results in diminished regional tumor burden.\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM I: Patients receive sargramostim subcutaneously (SC) 3-5 days prior to undergoing\n      sentinel lymph node biopsy.\n\n      ARM II: Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph\n      node biopsy.\n\n      After completion of study treatment, patients are followed up for 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with stage IB or II cutaneous melanoma\n\n          -  Primaries on the torso, upper and lower extremities and head and neck region\n\n          -  Skin biopsy performed at least 5 days and no longer than 10 weeks from the time of\n             initial entry into the study\n\n          -  Bilirubin < 2.0 ng/dl\n\n          -  Creatinine < 3.0 ng/dl\n\n          -  Able to understand the consent competent to sign\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n        Exclusion Criteria:\n\n          -  Prior wide excision with diameter of the excision > 3 cm\n\n          -  Primary melanoma arises from the eye or mucus membranes\n\n          -  Clinical evidence of regional, intransit ,or distant metastases\n\n          -  Second invasive melanoma\n\n          -  Prior surgical procedures that would alter the drainage patterns and would prevent us\n             from identifying sentinel lymph nodes (SN)\n\n          -  Patients with primary or secondary immunodeficiencies\n\n          -  Pregnancy\n\n          -  Known allergy to sargramostim (GM-CSF)\n\n          -  History of cardiac disease, in particular, supraventricular tachycardia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "380", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826864", 
            "org_study_id": "11-002177", 
            "secondary_id": [
                "NCI-2013-00645", 
                "11-002177"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm I (sargramostim and sentinel lymph node biopsy)", 
                "description": "Given SC", 
                "intervention_name": "sargramostim", 
                "intervention_type": "Biological", 
                "other_name": [
                    "GM-CSF", 
                    "Leukine", 
                    "Prokine"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (sargramostim and sentinel lymph node biopsy)", 
                    "Arm II (hypertonic saline and sentinel lymph node biopsy)"
                ], 
                "description": "Undergo sentinel lymph node biopsy", 
                "intervention_name": "sentinel lymph node biopsy", 
                "intervention_type": "Procedure", 
                "other_name": "sentinel node biopsy"
            }, 
            {
                "arm_group_label": [
                    "Arm I (sargramostim and sentinel lymph node biopsy)", 
                    "Arm II (hypertonic saline and sentinel lymph node biopsy)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm II (hypertonic saline and sentinel lymph node biopsy)", 
                "description": "Given SC", 
                "intervention_name": "hypertonic saline", 
                "intervention_type": "Other", 
                "other_name": "HTS"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "contact": {
                "email": "ressner@mednet.ucla.edu", 
                "last_name": "Richard Essner", 
                "phone": "310-825-5268"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095"
                }, 
                "name": "Jonsson Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Richard Essner", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase III Trial to Compare the Immunodulatory Effects of Leukine vs. Saline for Early-stage Melanoma Patients Undergoing Sentinel Lymph Node Dissection", 
        "overall_official": {
            "affiliation": "Jonsson Comprehensive Cancer Center", 
            "last_name": "Richard Essner", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A series of analysis of variance (ANOVA) models will be employed.", 
                "measure": "Reversal of alterations in the SN", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days"
            }, 
            {
                "description": "The primary analysis will be a two group continuity corrected Chi-squared test. A logistic regression analysis will also be run.", 
                "measure": "Proportion of subjects with positive SN in each group", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826864"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A two sample t-test will be used.", 
                "measure": "Disease free survival (DFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days"
            }, 
            {
                "description": "A two sample t-test will be used.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days"
            }
        ], 
        "source": "Jonsson Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Jonsson Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}